BiotechTube
3D BioLabs

3D BioLabs

Sarajevo, Europe - Other· Est.
bio.fablab.ba
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 2015, 3D BioLabs is a private, pre-revenue biotech firm operating at the intersection of 3D bioprinting, tissue engineering, and regenerative medicine. The company is developing a platform technology to create three-dimensional tissue constructs, positioning itself in the high-growth cell therapy and organ repair markets. Based in Sarajevo, it represents an emerging player in the European biotech innovation landscape, though detailed public information on its pipeline and leadership is limited. Its progress and validation will depend on securing partnerships, funding, and advancing its technology toward preclinical proof-of-concept.

Regenerative Medicine

Technology Platform

3D bioprinting and tissue engineering platform combining bioprinter hardware, bioink formulations, and potentially synthetic biology-engineered cells to create functional human tissue constructs.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global regenerative medicine market offers massive growth potential, driven by organ donor shortages and demand for advanced drug testing models.
Positioning in Europe provides access to structured regulatory pathways (EMA ATMP) and potential EU research funding.
The convergence of 3D bioprinting with synthetic biology allows for creating next-generation 'smart' tissues with enhanced therapeutic functions.

Risk Factors

The company faces immense technical hurdles in creating vascularized, functional tissues and navigating a complex, costly regulatory landscape for engineered biological products.
Its location outside major biotech hubs may hinder access to specialized talent, venture capital, and large pharmaceutical partners.
As a pre-revenue, early-stage platform company, it carries high risk of failure before achieving technical proof-of-concept or securing sustainable funding.

Competitive Landscape

3D BioLabs competes in a crowded and well-funded global field with companies like Organovo, CELLINK (now BICO), Prellis Biologics, and numerous academic spin-offs. Competition is based on bioprinting technology fidelity, bioink performance, speed, scalability, and the biological functionality of the final tissue construct. The company's small size and limited disclosed progress place it at a potential disadvantage against larger, more established players.

More companies in Regenerative Medicine →More companies in Europe - Other →